RecruitingPhase 2NCT06711471

Trifluridine/tipiracil (TAS-102), Bevacizumab, and Camrelizumab As Third-line or Later-line Therapy of Gastric Cancer

Phase II Study of Trifluridine/tipiracil (TAS-102), Bevacizumab, and Camrelizumab As a Third-line or Later-line Therapy for Patients with Metastatic Gastric Cancer

Sponsor

LIN YANG

Enrollment

31 participants

Start Date

Nov 14, 2024

Study Type

INTERVENTIONAL

Conditions

Gastric Cancer Adenocarcinoma Metastatic

Summary

For patients with metastatic gastric cancer, the efficacy of current standard treatments outlined in the guidelines is far from meeting the clinical demand. This study aims to explore the efficacy and safety of trifluridine/tipiracil (TAS-102), bevacizumab plus camrelizumab as a novel third-line or later-line therapy for metastatic gastric cancer patients.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study tests a three-drug combination — trifluridine/tipiracil (TAS-102), bevacizumab (an anti-blood vessel drug), and camrelizumab (an immunotherapy) — as a third or later-line treatment for advanced stomach or gastro-esophageal junction cancer. **You may be eligible if...** - You are 18 or older with confirmed advanced stomach or gastro-esophageal junction cancer (Stage IV) - You have already received at least two prior treatment regimens - You are in reasonably good health (ECOG 0–2) - Your blood counts and organ function meet required levels **You may NOT be eligible if...** - You have not received prior systemic treatment for this cancer - Your overall health status has declined significantly in the last 2 weeks - Your blood counts or organ function are below required thresholds Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGtrifluridine/tipiracil (TAS-102), bevacizumab plus camrelizumab

Patients enrolled in this study will receive trifluridine/tipiracil in combination with bevacizumab and camrelizumab, with a treatment cycle of 14 days, until disease progression, death, intolerable toxicity, or other criteria for discontinuation of study treatment as specified in the protocol (whichever occurs first).

Locations(1)

Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Beijing, Beijing Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06711471

Related Trials

Safety and Efficacy of Fruquintinib Plus Nab-Paclitaxel and Iparomlimab and Tuvonralimab Injection in the Second-Line Treatment for Immunotherapy-experienced Advanced Gastric Cancer

NCT073923461 location

A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer

NCT0692183716 locations

Phase II RAINSPOT: Zolbetuximab-Paclitaxel-Ramucirumab for CLDN18.2 Positive Gastro-esophageal Cancer

NCT069621376 locations